Skip to main content
Nextage Therapeutics Ltd. logo

Nextage Therapeutics Ltd. — Investor Relations & Filings

Ticker · NXTG ISIN · IL0004330119 TA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 11 across all filing types
Latest filing 2026-03-11 Regulatory Filings
Country IL Israel
Listing TA NXTG

About Nextage Therapeutics Ltd.

https://www.nextage-thera.com/

Nextage Therapeutics Ltd. is a pharmaceutical company focused on the development of cannabinoid-based therapeutic products. The company utilizes a proprietary drug delivery platform, including a brain-targeting liposome system, to enhance the delivery and efficacy of active pharmaceutical ingredients. Originating from Nextar Chempharma Solutions, a contract development and manufacturing organization (CDMO), Nextage leverages expertise in chemical and product development to create innovative treatments. The company's activities also include providing product development services within the pharmaceutical sector.

Recent filings

Filing Released Lang Actions
Change at the Company and Share names following transfer to the Maintenance list
Regulatory Filings Classification · 1% confidence The document is a short circular from the Tel Aviv Stock Exchange regarding a change in the listing status (maintenance list) and ticker symbol for Nextage Therapeutics Ltd. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general regulatory announcement from an exchange, it falls under the RNS category.
2026-03-11 English
Trading in the company's shares will renewed on March 12, 2026, on the maintenance list
Regulatory Filings Classification · 1% confidence The document is an official notice from the Tel-Aviv Stock Exchange (TASE) regarding the suspension and subsequent renewal of trading for Nextage Therapeutics Ltd. It discusses the status of the company's listing and the conditions for potential future delisting. Since it is a regulatory announcement from an exchange regarding trading status rather than a company-issued report or a specific delisting event, it falls under the general regulatory filings category.
2026-03-10 English
Suspension of trade due to failure in publishing financial reports-Notification
Regulatory Filings Classification · 1% confidence The document is a formal notice from the Tel Aviv Stock Exchange (TASE) regarding the suspension of trading for specific companies due to their failure to publish financial reports by the required deadline. It is a regulatory announcement issued by the exchange, not a financial report itself, and does not fit into specific categories like M&A or dividend announcements. Therefore, it falls under the general regulatory filings category.
2025-09-28 English
The sector classification of NEXTAGE THERAPEUTICS will be changed, as of April 10, 2025 from – BIOMED – INVESTMENT IN LIFE SCIENCES, to– BIOMED - BIOTECHNOLOGY
Regulatory Filings
2025-04-08 Hebrew (modern)
Discontinuation of Market Making
Regulatory Filings
2025-01-19 Hebrew (modern)
Opening of Trading On February 3 2022-NEXTAGE W27
Regulatory Filings
2022-02-02 Hebrew (modern)

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.